Dr. Tara Gangadhar on Single-Agent Versus Dual Immunotherapy Approaches in Melanoma
March 15th 2016Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.